| Literature DB >> 28440103 |
R Hamish McAllister-Williams1,2, David S Baldwin3,4, Roch Cantwell5, Abby Easter6, Eilish Gilvarry2,7, Vivette Glover8, Lucian Green9, Alain Gregoire3,10, Louise M Howard11,12, Ian Jones13, Hind Khalifeh11,12, Anne Lingford-Hughes14, Elizabeth McDonald15,16,17, Nadia Micali18, Carmine M Pariante12,19, Lesley Peters20, Ann Roberts20,21,22, Natalie C Smith23, David Taylor12,24, Angelika Wieck25,26, Laura M Yates27,28, Allan H Young12,19.
Abstract
Decisions about the use of psychotropic medication in pregnancy are an ongoing challenge for clinicians and women with mental health problems, owing to the uncertainties around risks of the illness itself to mother and fetus/infant, effectiveness of medications in pregnancy and risks to the fetus/infant from in utero exposure or via breast milk. These consensus guidelines aim to provide pragmatic advice regarding these issues. They are divided into sections on risks of untreated illness in pregnancy; general principles of using drugs in the perinatal period; benefits and harms associated with individual drugs; and recommendations for the management of specific disorders.Entities:
Keywords: Antidepressants; antipsychotics; anxiolytics; birth defects; breastfeeding; child development; conception; fertility; hypnotics; mood stabilisers; neonatal problems; postpartum; pregnancy; pregnancy outcome; psychiatric illness; psychotropics; teratogenicity
Mesh：
Substances：
Year: 2017 PMID： 28440103 DOI： 10.1177/0269881117699361
Source DB: PubMed Journal: J Psychopharmacol ISSN： 0269-8811 Impact factor: 4.153